Frank Buchholz shares how his laboratory improves upon the latest gene editing techniques by designing programmable ...

CRSP is a speculative buy for aggressive investors, driven by the commercial launch and multibillion-dollar potential of ...

Scientists used CRISPR to reactivate uricase, an enzyme humans lost millions of years ago. Restoring the gene in liver cells ...

Another major buy was in INTELLIA THERAPEUTICS INC (NASDAQ:NTLA), with ARK purchasing 191,705 shares for around $2.18 million through its ARKK ETF. Similar to CRISPR, INTELLIA has seen increased ...